Journal List > Int J Thyroidol > v.12(2) > 1138974

Int J Thyroidol. 2019 Nov;12(2):85-90. Korean.
Published online Nov 30, 2019.  https://doi.org/10.11106/ijt.2019.12.2.85
Copyright © 2019. the Korean Thyroid Association
Updates of Radioiodine Treatment for Graves' Disease
Shin Young Jeong
Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.

Correspondence: Shin Young Jeong, MD, PhD, Department of Nuclear Medicine, Kyungpook National University Chilgok Hospital, 807 Hoguk-ro, Buk-gu, Daegu 41404, Korea. Tel: 82-53-200-2852, Fax: 82-53-200-3419, Email: syjeong@knu.ac.kr
Received Sep 24, 2019; Revised Oct 18, 2019; Accepted Oct 27, 2019.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Abstract

Radioiodine (RAI) has been used for the treatment of hyperthyroidism and is usually administered orally as sodium iodide (I-131) in solution or a capsule. However, this results in RAI being rapidly incorporated into the thyroid cells, and extensive local tissue damage occurring via beta emissions of I-131. The incidence rate of hypothyroidism is 5–50% at the first year after RAI therapy and is positively associated with the dosage of RAI. RAI has been used since 1960 in Korea; however, there have been few well-designed prospective trials, leaving many questions about indications, optimal dose, efficacy, and side-effects. This review summarizes the latest research pertaining to clinical questions about indications, optimal dose, efficacy, and side-effects.

Keywords: Radioactive iodine; Graves' disease; Thyroid; Hyperthyroidism

References
1. Seo GH, Kim SW, Chung JH. Incidence & prevalence of hyperthyroidism and preference for therapeutic modalities in Korea. J Korean Thyroid Assoc 2013;6(1):56–63.
2. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves' disease. J Clin Endocrinol Metab 2012;97(12):4549–4558.
3. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves' disease. Clin Endocrinol (Oxf) 2016;84(1):115–120.
4. Vaidya B, Williams GR, Abraham P, Pearce SH. Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf) 2008;68(5):814–820.
5. Walsh JP. Management of Graves' disease in Australia. Aust N Z J Med 2000;30(5):559–566.
6. Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev 2012;33(6):920–980.
7. Yi KH, Moon JH, Kim IJ, Bom HS, Lee J, Chung WY, et al. The diagnosis and management of hyperthyroidism consensus - Report of the Korean Thyroid Association. J Korean Thyroid Assoc 2013;6(1):1–11.
8. Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. Eur Thyroid J 2018;7(4):167–186.
9. Franklyn JA. The management of hyperthyroidism. N Engl J Med 1994;330(24):1731–1738.
10. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016;26(10):1343–1421.
11. Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthyroidism. Ther Clin Risk Manag 2010;6:29–40.
12. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest 1995;25(3):186–193.
13. Jarløv AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) 1995;43(3):325–329.
14. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab 2003;88(3):978–983.
15. Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and dosimetric variables related to outcome after treatment of Graves' disease with 550 and 1110 MBq of 131I: results of a prospective randomized trial. Clin Nucl Med 2015;40(9):715–719.
16. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab 2002;87(3):1073–1077.
17. Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in Graves' disease: a meta-analysis of randomized controlled trials. Br J Radiol 2016;89(1064):20160418
18. Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA. Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 2013;98(5):1869–1882.
19. Brandt F, Thvilum M, Almind D, Christensen K, Green A, Hegedus L, et al. Graves' disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid 2013;23(4):408–413.
20. Giesecke P, Rosenqvist M, Frykman V, Friberg L, Wallin G, Hoijer J, et al. Increased cardiovascular mortality and morbidity in patients treated for toxic nodular goiter compared to Graves' disease and nontoxic goiter. Thyroid 2017;27(7):878–885.
21. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 2007;92(6):2190–2196.
22. Nyirenda MJ, Clark DN, Finlayson AR, Read J, Elders A, Bain M, et al. Thyroid disease and increased cardiovascular risk. Thyroid 2005;15(7):718–724.
23. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA 2005;294(1):71–80.
24. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med 1998;338(11):712–718.
25. Goldman MB, Maloof F, Monson RR, Aschengrau A, Cooper DS, Ridgway EC. Radioactive iodine therapy and breast cancer. A follow-up study of hyperthyroid women. Am J Epidemiol 1988;127(5):969–980.
26. Okosieme OE, Taylor PN, Evans C, Thayer D, Chai A, Khan I, et al. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol 2019;7(4):278–287.
27. Ljunggren JG, Torring O, Wallin G, Taube A, Tallstedt L, Hamberger B, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998;8(8):653–659.
28. Abraham-Nordling M, Torring O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, et al. Graves' disease: a long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005;15(11):1279–1286.
29. Cramon P, Winther KH, Watt T, Bonnema SJ, Bjorner JB, Ekholm O, et al. Quality-of-life impairments persist six months after treatment of Graves' hyperthyroidism and toxic nodular goiter: a prospective cohort study. Thyroid 2016;26(8):1010–1018.
30. Bove KB, Watt T, Vogel A, Hegedus L, Bjoerner JB, Groenvold M, et al. Anxiety and depression are more prevalent in patients with graves' disease than in patients with nodular goitre. Eur Thyroid J 2014;3(3):173–178.
31. Elberling TV, Rasmussen AK, Feldt-Rasmussen U, Hording M, Perrild H, Waldemar G. Impaired health-related quality of life in Graves' disease. A prospective study. Eur J Endocrinol 2004;151(5):549–555.
32. Torring O, Watt T, Sjolin G, Bystrom K, Abraham-Nordling M, Calissendorff J, et al. Impaired quality of life after radioiodine therapy compared to antithyroid drugs or surgical treatment for Graves' hyperthyroidism: a long-term follow-up with the thyroid-related patient-reported outcome questionnaire and 36-item short form health status survey. Thyroid 2019;29(3):322–331.
33. Abraham-Nordling M, Wallin G, Traisk F, Berg G, Calissendorff J, Hallengren B, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol 2010;163(4):651–657.
34. Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al. Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol (Oxf) 2001;54(3):391–398.
35. Yeatts RP. Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc 2005;103:368–411.
36. Wartofsky L. Therapeutic controversies. Summation, commentary, and overview: concerns over aggravation of Graves' ophthalmopathy by radioactive iodine treatment and the use of retrobulbar radiation therapy. J Clin Endocrinol Metab 1995;80(2):347–349.
37. Taieb D, Bournaud C, Eberle MC, Catargi B, Schvartz C, Cavarec MB, et al. Quality of life, clinical outcomes and safety of early prophylactic levothyroxine administration in patients with Graves' hyperthyroidism undergoing radioiodine therapy: a randomized controlled study. Eur J Endocrinol 2016;174(4):491–502.
38. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338(2):73–78.
39. Acharya SH, Avenell A, Philip S, Burr J, Bevan JS, Abraham P. Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review. Clin Endocrinol (Oxf) 2008;69(6):943–950.
40. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008;158(1):69–75.
41. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321(20):1349–1352.
42. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158(3):273–285.
43. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17(3):456–520.
44. Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, et al. Radioiodine-associated exacerbation of Graves' orbitopathy in the Japanese population: randomized prospective study. J Clin Endocrinol Metab 2015;100(7):2700–2708.